Sanofi-Genzyme BioVentures (SGBV) is an important component of Sanofi’s broader global strategy to invigorate external innovation and research that will ultimately lead to new products. SGBV has leveraged the venture capital investment expertise and platform of its predecessor fund, Genzyme Ventures, with a recently-expanded mandate to invest across the more expansive footprint of Sanofi.
Originally established in 2001 as Genzyme Ventures, SGBV invests directly in private early-stage companies with promising new products based on breakthrough science. Today, SGBV is a $100 million fund with a portfolio of direct equity investments in a variety of promising private life-science companies.
|bluebird bio||3/10||Series B||$35M||5|
|Fate Therapeutics||11/09||Series B||$30M||6|
|KaloBios Pharmaceuticals||12/08||Series D||$12M||8|
|Proteostasis Therapeutics||8/08||Series A||$45M||5|
|TcLand Expression||12/07||Series A||€8.2M||4|
|Sirtris Pharmaceuticals||4/06||Series C||$37M||2|